BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 35448166)

  • 1. Whole-Exome Sequencing Identifies the VHL Mutation (c.262T > C, p.Try88Arg) in Non-Obstructive Azoospermia-Associated Cystic Renal Cell Carcinoma.
    Man Y; Shang X; Liu C; Zhang W; Huang Q; Ma S; Shiang R; Zhang F; Zhang L; Zhang Z
    Curr Oncol; 2022 Mar; 29(4):2376-2384. PubMed ID: 35448166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of VHL missense mutations in sporadic clear cell renal cell carcinoma: hotspots, affected binding domains, functional impact on pVHL and therapeutic relevance.
    Razafinjatovo C; Bihr S; Mischo A; Vogl U; Schmidinger M; Moch H; Schraml P
    BMC Cancer; 2016 Aug; 16():638. PubMed ID: 27530247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined deletion of Vhl, Trp53 and Kif3a causes cystic and neoplastic renal lesions.
    Guinot A; Lehmann H; Wild PJ; Frew IJ
    J Pathol; 2016 Jul; 239(3):365-73. PubMed ID: 27126173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Germline mutations in the VHL gene associated with 3 different renal lesions in a Chinese von Hippel-Lindau disease family.
    Yuan P; Sun Q; Liang H; Wang W; Li L; Wang Y; Deng H; Lai L; Chen X; Zhou X
    Cancer Biol Ther; 2016 Jun; 17(6):599-603. PubMed ID: 27057652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
    Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
    Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bap1 is essential for kidney function and cooperates with Vhl in renal tumorigenesis.
    Wang SS; Gu YF; Wolff N; Stefanius K; Christie A; Dey A; Hammer RE; Xie XJ; Rakheja D; Pedrosa I; Carroll T; McKay RM; Kapur P; Brugarolas J
    Proc Natl Acad Sci U S A; 2014 Nov; 111(46):16538-43. PubMed ID: 25359211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. VHL missense mutations in the p53 binding domain show different effects on p53 signaling and HIFα degradation in clear cell renal cell carcinoma.
    Razafinjatovo CF; Stiehl D; Deininger E; Rechsteiner M; Moch H; Schraml P
    Oncotarget; 2017 Feb; 8(6):10199-10212. PubMed ID: 28052007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma.
    Perier A; Fregni G; Wittnebel S; Gad S; Allard M; Gervois N; Escudier B; Azzarone B; Caignard A
    Oncogene; 2011 Jun; 30(23):2622-32. PubMed ID: 21258414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel missense mutation (N78D) in a family with von Hippel-Lindau disease with central nervous system haemangioblastomas, pancreatic and renal cysts.
    Cingoz S; van der Luijt RB; Kurt E; Apaydin M; Akkol I; Ozgen MH
    Fam Cancer; 2013 Mar; 12(1):111-7. PubMed ID: 23224817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An integrated computational approach can classify VHL missense mutations according to risk of clear cell renal carcinoma.
    Gossage L; Pires DE; Olivera-Nappa Á; Asenjo J; Bycroft M; Blundell TL; Eisen T
    Hum Mol Genet; 2014 Nov; 23(22):5976-88. PubMed ID: 24969085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrative analysis of dysregulated microRNAs and mRNAs in multiple recurrent synchronized renal tumors from patients with von Hippel-Lindau disease.
    Gattolliat CH; Couvé S; Meurice G; Oréar C; Droin N; Chiquet M; Ferlicot S; Verkarre V; Vasiliu V; Molinié V; Méjean A; Dessen P; Giraud S; Bressac-De-Paillerets B; Gardie B; Tean Teh B; Richard S; Gad S
    Int J Oncol; 2018 Oct; 53(4):1455-1468. PubMed ID: 30066860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal cell carcinoma- and pheochromocytoma-specific altered gene expression profiles in VHL mutant clones.
    Tsuchiya MI; Okuda H; Takaki Y; Baba M; Hirai S; Ohno S; Shuin T
    Oncol Rep; 2005 Jun; 13(6):1033-41. PubMed ID: 15870918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Familial clear cell renal cell carcinoma (FCRC): clinical features and mutation analysis of the VHL, MET, and CUL2 candidate genes.
    Woodward ER; Clifford SC; Astuti D; Affara NA; Maher ER
    J Med Genet; 2000 May; 37(5):348-53. PubMed ID: 10807693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. VHL, the story of a tumour suppressor gene.
    Gossage L; Eisen T; Maher ER
    Nat Rev Cancer; 2015 Jan; 15(1):55-64. PubMed ID: 25533676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and functional properties of novel VHL mutation (X214L) consistent with Type 2A phenotype and low risk of renal cell carcinoma.
    Sorrell AD; Lee S; Stolle C; Ellenhorn J; Grix A; Kaelin WG; Weitzel JN
    Clin Genet; 2011 Jun; 79(6):539-45. PubMed ID: 20560986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three novel germ-line VHL mutations in Hungarian von Hippel-Lindau patients, including a nonsense mutation in a fifteen-year-old boy with renal cell carcinoma.
    Losonczy G; Fazakas F; Pfliegler G; Komáromi I; Balázs E; Pénzes K; Berta A
    BMC Med Genet; 2013 Jan; 14():3. PubMed ID: 23298237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deubiquitylase OTUD6B stabilizes the mutated pVHL and suppresses cell migration in clear cell renal cell carcinoma.
    Guo K; Wei Y; Wang Z; Zhang X; Zhang X; Liu X; Wu W; Wu Z; Zhang L; Cui CP
    Cell Death Dis; 2022 Feb; 13(2):97. PubMed ID: 35110537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The expression of hypoxia inducible factor-1,2 alpha in sporadic clear cell renal cell carcinoma and their relationships to the mutations of von Hippel-Lindau gene].
    Gong K; Zhang N; Na X; Wu G; Yang XY; Xin DQ; Na YQ
    Zhonghua Wai Ke Za Zhi; 2005 Mar; 43(6):390-3. PubMed ID: 15854350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unique molecular alteration patterns in von Hippel-Lindau (VHL) gene in a cohort of sporadic renal cell carcinoma patients from Pakistan.
    Khaliq S; Ajaz S; Firasat S; Shahid S; Hasan AS; Sultan G; Mohsin R; Hashmi A; Mubarak M; Naqvi SA; Rizvi SA; Mehdi SQ; Abid A
    Mutat Res; 2014; 763-764():45-52. PubMed ID: 24727139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differentiation of clear cell and non-clear cell renal cell carcinomas by all-relevant radiomics features from multiphase CT: a VHL mutation perspective.
    Li ZC; Zhai G; Zhang J; Wang Z; Liu G; Wu GY; Liang D; Zheng H
    Eur Radiol; 2019 Aug; 29(8):3996-4007. PubMed ID: 30523454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.